The John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease was held virtually for the first time in its sixteen-year history. We are pleased this allowed for a wider audience but are very much looking forward to welcoming you back to the Royal Society, London in 2022.
In the meantime, those of you who attended this year will be able to revisit the presentations using the links below (your password has been emailed to you). We hope you enjoy!
Roberto Badagliacca: Risk Reduction and Haemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension
Michele D’Alto: Risk Reduction and Right Heart Reverse Remodelling by Upfront Triple Combination Therapy in PAH
Anna Hemnes: Patient Stratification in PAH
James Klinger: Mesenchymal Stem Cell Extracellular Vesicles for the Treatment of Pulmonary Hypertension
Irene Lang: Advances in Balloon Pulmonary Angioplasty for the treatment of non-operable CTEPH
Sarah MacRae: Palliative Care in PAH
Nick Morrell: Polyamines and PAH
Robert Naeije: Non-Invasive Methods to assess PAH
Steven Nathan: Pulmonary Hypertension in Chronic Lung Disease
Olivier Sitbon: Emerging Endpoints in PAH
David Smadja: Prostacyclin Analogues and Non-Vasodilator Effects: Is there any Antithrombotic Effect in PAH?
Khodr Tello: Evaluation and Prognostic Relevance of Right Ventricular-Arterial Coupling in Pulmonary Hypertension
Chris Thiemermann: Welcome
Mark Toshner: Targeting Inflammation in PAH: Twist, Stick or Fold?
Raman Venkataramanan: Prostacyclins to Protect Ischaemia and Reperfusion Injury of Organs for Transplantation
Dario Vizza: Afterload Reduction in the Early Use of Prostacyclin
Jim White: What have we learnt today?
Jim White: Getting the Most out of the 6-Minute Walk
